Category: Bayer HealthCare
Is KKR-backed Panasonic Health a match for the long rumored sale of Bayer's diabetes device business?
(Reuters) - German drugmaker Bayer AG is close to selling its diabetes devices business to KKR-backed Panasonic Healthcare Holdings Co Ltd and the unit could be valued at up to $2.3 billion, Bloomberg news reported.
Bayer is reportedly exploring a sale of its diabetes device business, which could fetch as much as $2.5 billion from interested private equity buyers.
(Reuters) — Bayer (PINK:BAYRY) is considering the sale of its diabetes device business, Bloomberg reported, citing sources.
Boston Scientific says it's closed the $415 million acquisition of Bayer AG's interventions unit, nearly doubling the size of its peripherals business.
Boston Scientific (NYSE:BSX) said today that it closed on the $415 million cash buyout of Bayer AG's interventional unit it announced last May.
Here's a look at some of the top Wall Street stories for medical device companies this week: Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?; M&A: Medtech makers use acquisitions to fill niches; Report: Deals in the medical device sector rose 200% in Q1; CareFusion plans $1B debt offering; Activist investor Oracle revives proxy war at Biolase.
Cardiovascular Systems' shares drop as Boston Scientific positions itself as a peripherals market rival with the $415 million acquisition of Bayer AG's interventional business.
Boston Scientific's (NYSE:BSX) $415 million acquisition of Bayer AG's interventional unit is a strong move for the company, but it may bode ill for other peripheral players.
Boston Scientific agrees to a $415 million deal to add Bayer's interventional business to its peripheral interventions unit, adding thrombectomy and atherectomy devices to its portfolio.
Boston Scientific (NYSE:BSX) said it agreed to acquire Bayer AG's interventional unit for $415 million, in a move to significantly bolster its own $200 million peripheral interventions business.